RELISTOR INJECTION Rx
Generic Name and Formulations:
Methylnaltrexone bromide 8mg/0.4mL, 12mg/0.6mL; soln for SC inj.
Valeant Pharmaceuticals, Inc
Indications for RELISTOR INJECTION:
Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its treatment in patients who do not require frequent opioid dosage escalation. OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care.
Limitations Of use:
Use for >4 months has not been studied in the advanced illness population.
Give by SC inj in upper arm, abdomen, or thigh; rotate inj sites. Chronic non-cancer pain: Discontinue all maintenance laxatives prior to initiation; may be used if suboptimal methylnaltrexone response after 3 days. Reevaluate if opioid regimen is changed. Give 12mg once daily. Advanced illness: Give once every other day as needed (max 1 dose/24hrs). <38kg or >114kg: 0.15mg/kg. 38–<62kg: 8mg. 62–114kg: 12mg. Moderate or severe renal impairment (CrCl<60mL/min): reduce dose by ½ (see full labeling). Severe hepatic impairment: may consider reducing weight-based dose by ½ (non-cancer pain only). Prefilled syringes: use only for 8mg or 12mg fixed doses.
Known or suspected GI obstruction and at increased risk of recurrent obstruction.
Discontinue if concurrent opioid pain medication is also discontinued. GI perforation; monitor for severe, persistent, or worsening abdominal pain; discontinue if occurs. Discontinue if severe or persistent diarrhea occurs. Increased risk of opioid withdrawal and/or reduced analgesia in those with blood-brain barrier disruptions; monitor for symptoms. Bowel movement may occur within 30 mins of dosing. Elderly. Pregnancy. Nursing mothers: not recommended.
Opioid antagonist (peripheral).
Potential additive effects and increased risk of opioid withdrawal with concomitant other opioid antagonists; avoid.
Abdominal pain, flatulence, nausea, dizziness, diarrhea, headache, abdominal distention, vomiting, hyperhidrosis, anxiety, muscle spasms, rhinorrhea, chills, tremor, hot flush; GI perforation, opioid withdrawal.
Tabs—60, 90; Single-use vial (12mg/0.6mL)—1; Prefilled syringes (8mg/0.4mL)—7; Prefilled syringes (12mg/0.6mL)—1, 7
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|